Latest filings (excl ownership)
6-K
Current report (foreign)
16 Jan 24
6-K
Current report (foreign)
22 Dec 23
6-K
Current report (foreign)
22 Dec 23
6-K
Current report (foreign)
5 Dec 23
6-K
Current report (foreign)
17 Nov 23
6-K
Current report (foreign)
17 Nov 23
6-K
Cellectis Announces the execution of the Subsequent Investment Agreement with AstraZeneca
15 Nov 23
6-K
Joint Researchand Collaboration Agreement
9 Nov 23
6-K
Cellectis Reports Financial Results for Third Quarter and First Nine Months 2023
6 Nov 23
6-K
Current report (foreign)
6 Nov 23
6-K
Current report (foreign)
2 Nov 23
6-K
Current report (foreign)
1 Nov 23
6-K
Cellectis Announces Strategic Collaboration and Investment Agreements with AstraZeneca
1 Nov 23
20-F/A
2022 FY
Annual report (foreign) (amended)
31 Oct 23
6-K
Current report (foreign)
31 Oct 23
6-K
Current report (foreign)
31 Oct 23
6-K
Cellectis to Present Pre-Clinical Data on HSPC Gene Therapy Program and Comprehensive Analysis of TALE-BE at the ESGCT 30th Annual Congress
24 Oct 23
6-K
Current report (foreign)
12 Oct 23
6-K
Current report (foreign)
27 Sep 23
6-K/A
Current report (foreign) (amended)
5 Sep 23
S-8
Registration of securities for employees
7 Aug 23
6-K
Cellectis Provides Full Report for Second Quarter 2023 Financial Results
7 Aug 23
6-K
Current report (foreign)
7 Aug 23
6-K
Cellectis Provides Business Updates and Preliminary Financial Results for Second Quarter 2023
3 Aug 23
6-K
Current report (foreign)
27 Jul 23
6-K
Cellectis Appoints Dr. Cécile Chartier, Ph.D. to its Board of Directors
12 Jul 23
6-K
Current report (foreign)
29 Jun 23
6-K
Current report (foreign)
28 Jun 23
6-K
Cellectis Presents Updated Clinical and Translational Data on BALLI-01 at the European Hematology Association (EHA) 2023
9 Jun 23
6-K
Current report (foreign)
5 Jun 23
6-K
Current report (foreign)
31 May 23
6-K
Current report (foreign)
22 May 23
6-K
Cellectis Presents Clinical Data on AMELI-01 and Preclinical Data on Multiplex Engineering for Superior Generation of CAR T-cells at ASGCT 2023
17 May 23
6-K
Current report (foreign)
12 May 23
6-K
Cellectis Announces Poster Presentation on BALLI-01 at the European Hematology Association (EHA) 2023
11 May 23
6-K
Current report (foreign)
4 May 23
6-K
Current report (foreign)
2 May 23
6-K
Current report (foreign)
27 Apr 23
6-K
Cellectis Implements CLLS52 for the First Time in the Clinic with Sanofi’s Alemtuzumab
24 Apr 23
6-K
Current report (foreign)
17 Apr 23
Latest ownership filings
SC 13G/A
Long Focus Capital Management, LLC
14 Feb 24
SC 13G/A
PFIZER INC
14 Feb 24
SC 13G/A
BAILLIE GIFFORD & CO
5 Dec 23
SC 13D/A
ASTRAZENECA PLC
16 Nov 23
SC 13D/A
Bpifrance Participations SA
13 Nov 23
SC 13D
ASTRAZENECA PLC
9 Nov 23
SC 13D/A
Cibus, Inc.
1 Jun 23
SC 13G/A
Long Focus Capital Management, LLC
14 Feb 23
SC 13D/A
Bpifrance Participations SA
14 Feb 23
SC 13G/A
BAILLIE GIFFORD & CO
18 Jan 23
SC 13D/A
Calyxt, Inc.
17 Jan 23
SC 13D/A
Calyxt, Inc.
1 Nov 22
SC 13G
Long Focus Capital Management, LLC
3 May 22
SC 13G/A
Capital International Investors
11 Feb 22
SC 13G/A
ARK Investment Management LLC
9 Feb 22
SC 13G
BAILLIE GIFFORD & CO
12 Jan 22
SC 13G/A
Capital International Investors
16 Feb 21
SC 13G/A
ARK Investment Management LLC
16 Feb 21
SC 13D/A
Bpifrance Participations SA
12 Feb 21
SC 13G/A
FMR LLC
8 Feb 21
SC 13G
ARK Investment Management LLC
10 Nov 20
SC 13D/A
Calyxt, Inc.
23 Oct 20
4
Calyxt, Inc.
20 Oct 20
SC 13D
Bpifrance Participations SA
4 Aug 20
SC 13D/A
Calyxt, Inc.
10 Jul 20
SC 13G
Beneficial ownership report
14 Feb 20
SC 13G/A
Beneficial ownership report (amended)
7 Feb 20
SC 13D/A
Calyxt, Inc.
23 Sep 19
SC 13G/A
Cellectis S.A.
13 Feb 19
SC 13D/A
Calyxt, Inc.
15 Jun 18
4
Calyxt, Inc.
15 Jun 18
SC 13D
Calyxt, Inc.
29 May 18
4
Calyxt, Inc.
21 May 18
SC 13G
Calyxt, Inc.
14 Feb 18
SC 13G/A
Cellectis S.A.
13 Feb 18
SC 13G/A
Cellectis S.A.
13 Feb 18
3
Calyxt, Inc.
20 Jul 17
SC 13G/A
Cellectis S.A.
15 Feb 17
SC 13G
Cellectis S.A.
14 Feb 17
SC 13G
Cellectis S.A.
13 Feb 17